Hainan Poly Pharm announced that its wholly-owned subsidiary, Zhejiang Poly Pharmaceutical Co., Ltd., recently received the drug clinical trial approval notice for the innovative drug injection PL002 issued by the National Medical Products Administration (NMPA). In October last year, PL002 was granted a clinical trial approval by the FDA in the usa for preoperative diagnosis and intraoperative navigation of primary liver cancer patients. The indication applied for domestically this time is preoperative diagnosis and intraoperative navigation for patients with brain gliomas.
普利制药：创新药注射用PL002获得中国药物临床试验批准
Hainan Poly Pharm: The innovative drug injection PL002 has received clinical trial approval in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha